Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Onco-Innovations Limited (C:ONCO)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ONCO within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 16, 2025 17:00 ET
Onco-Innovations' Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells
VANCOUVER, BC / ACCESS Newswire / January 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology"), which was shown in a study1 to successfully prevent the regeneration of ca
Read full article
Jan 09, 2025 16:45 ET
Onco-Innovations' Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness
VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed technology of a new class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (the "Technology"), which has shown in a study[1] to be effective in targeting and inactivating DNA repair processes in cancer cells, thereby potentially
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Dec 31, 2024 0 0
Dec 15, 2024 0 0
Dec 31, 1969 0 0
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $ONCO.CA

  • No tweets found